Complaints that the US FDA’s burden estimates for implementing a suffix-based nonproprietary naming system for all biologic products failed to take into account hundreds of millions of dollars in downstream costs may find a receptive audience in the Trump Administration.
Several stakeholders have requested the Office of Management and Budget (OMB) delay implementation of the suffix-based naming policy outlined in...